Results 41 to 50 of about 861 (122)

Clinical management of metastatic colorectal cancer in the era of precision medicine

CA: A Cancer Journal for Clinicians, Volume 72, Issue 4, Page 372-401, July/August 2022., 2022
Abstract Colorectal cancer (CRC) represents approximately 10% of all cancers and is the second most common cause of cancer deaths. Initial clinical presentation as metastatic CRC (mCRC) occurs in approximately 20% of patients. Moreover, up to 50% of patients with localized disease eventually develop metastases.
Fortunato Ciardiello, Davide Ciardiello, Giulia Martini, Stefania Napolitano, Josep Tabernero, Andres Cervantes   +5 more
wiley   +1 more source

Efficacy and safety of Ziv-aflibercept in patients with central retinal vein occlusion

Delta Journal of Ophthalmology, 2021
Background Retinal vein occlusion is one of the most common vascular disorders that can cause visual loss. It is classified into central retinal vein occlusion (CRVO) and branch retinal vein occlusion.
Amin E Nawar, Heba M Shafik
doaj   +1 more source

The survival benefit of increasing the number of active drugs for metastatic colorectal cancer: A multicenter retrospective study

Cancer Medicine, Volume 11, Issue 11, Page 2184-2192, June 2022., 2022
This multicenter retrospective study investigated whether a strategy of administering all available drugs leads to a better prognosis in metastatic colorectal cancer. Abstract Background The development of chemotherapy and treatment strategies for metastatic colorectal cancer (mCRC) have provided patients with significant survival benefits.
Takeshi Kawakami, Toshiki Masuishi, Yasuyuki Kawamoto, Hirofumi Go, Kyoko Kato, Ryosuke Kumanishi, Kentaro Sawada, Satoshi Yuki, Kouji Yamamoto, Yoshito Komatsu, Kei Muro, Kunihiro Fushiki, Hiromichi Shirasu, Kentaro Yamazaki   +13 more
wiley   +1 more source

A phase II study of anlotinib combined with etoposide and platinum‐based regimens in the first‐line treatment of extensive‐stage small cell lung cancer

Thoracic Cancer, Volume 13, Issue 10, Page 1463-1470, May 2022., 2022
Anlotinib (AL3818), an oral, small‐molecular tyrosine kinase inhibitor, was approved as a first third‐ and further‐line treatment regime of relapsed SCLC in China in 2019. This study showed that the addition of anlotinib to standard etoposide/platinum chemotherapy achieved encouraging PFS and OS in previously untreated extensive‐stage small cell lung ...
Chang Liu, Jiatao Liao, Xianghua Wu, Xinmin Zhao, Si Sun, Huijie Wang, Zhihuang Hu, Yao Zhang, Hui Yu, Jialei Wang   +9 more
wiley   +1 more source

Biological drug therapy for ocular angiogenesis: Anti‐VEGF agents and novel strategies based on nanotechnology

Pharmacology Research &Perspectives, Volume 9, Issue 2, April 2021., 2021
Higher concentrations of anti‐VEGF agents have been observed after ocular administration of nanoparticulate systems in the long‐term in comparison to those of solution formulations of the same agents. The improvements on therapy offered by these nanoparticulate systems have also been evidenced in the higher antiangiogenic properties reported in in ...
María L. Formica, Hamoudi G. Awde Alfonso, Santiago D. Palma   +2 more
wiley   +1 more source

New‐generation anticancer drugs and medication‐related osteonecrosis of the jaw (MRONJ): Late onset 3 years after ipilimumab endovenous administration with a possible role of target therapy

Clinical Case Reports, Volume 9, Issue 1, Page 61-66, January 2021., 2021
Association of immunotherapy and/or chemotherapy and/or targeted therapy, in sequence or as single therapies, may induce osteonecrosis of the jaw. Multidisciplinary team management of these patients should be provided. Abstract Association of immunotherapy and/or chemotherapy and/or targeted therapy, in sequence or as single therapies, may induce ...
Agostino Guida, Francesco Perri, Franco Ionna, Paolo A. Ascierto, Antonio M. Grimaldi   +4 more
wiley   +1 more source

Intravitreal Therapy for Diabetic Macular Edema: An Update

Journal of Ophthalmology, Volume 2021, Issue 1, 2021., 2021
Diabetic macular edema (DME) represents a prevalent and disabling eye condition. Despite that DME represents a sight‐threatening condition, it is also among the most accessible to treatment. Many different treatment options including photocoagulation, intravitreal medical treatment (either vascular endothelial growth factor inhibitors or ...
Claudio Furino, Francesco Boscia, Michele Reibaldi, Giovanni Alessio, Enrique Mencía-Gutiérrez   +4 more
wiley   +1 more source

Commentary: Ziv-aflibercept: An alternative antivascular endothelial growth factor agent for polypoidal choroidal vasculopathy

Indian Journal of Ophthalmology, 2019
Kumar Anshuman, Dhanashree Ratra
doaj   +2 more sources

Drug Monographs: Ziv-aflibercept and Vincristine Sulfate Liposome [PDF]

Hospital Pharmacy, 2013
The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases.
Jessica N, Lee, Dominic A, Solimando, J Aubrey, Waddell   +2 more
openaire   +2 more sources

pH of anti-VEGF agents in the human vitreous: low impact of very different formulations

International Journal of Retina and Vitreous, 2017
Background The aim of the study was to measure pH changes of the human vitreous caused by the intravitreal drugs bevacizumab, ranibizumab, aflibercept, and ziv-aflibercept.
Bianka Sobolewska, Peter Heiduschka, Karl-Ulrich Bartz-Schmidt, Focke Ziemssen   +3 more
doaj   +1 more source